

In the Claims:

1. (Cancelled)

2. (Cancelled)

3. (Cancelled)

4. (Cancelled)

5. (Cancelled)

6. (Cancelled)

7. (Cancelled)

8. (Cancelled)

9. (Cancelled)

10. (Cancelled)

11. (Cancelled)

12. (Cancelled)

13. (Cancelled)

14. (Cancelled)

15. (Cancelled)

16. (Cancelled)

17. (Cancelled)

18. (Cancelled)

19. (Cancelled)

20. (Cancelled)

21. (Currently amended) A method for ~~the screening and identification~~ identifying of a compound which inhibits atherosclerosis or restenosis comprising the use of PDE4 as a target, wherein said method comprises:

a) measuring phosphodiesterase activity of a PDE4 target,

b) administering a compound suspected to be an activator or inhibitor of PDE4 to the PDE4 target; and

c) measuring the activation or inhibition of the phosphodiesterase activity of PDE4 by the compound,

wherein inhibition of the phosphodiesterase activity of PDE4 would identify a compound which inhibits atherosclerosis or restenosis.

22. (Currently amended) The method of claim 21 wherein the PDE4D is selected from the group consisting of PDE4D, PDE4DS₅ and PDE4D7.

23. (Previously presented) The method of claim 22, wherein the PDE4 is PDE4D7.

24. (Canceled) The method of claim 21 further comprising increasing the activation or inhibition of the phosphodiesterase activity of PDE4 by the compound.

25. (Canceled) The method of claim 24, wherein the compound is an inhibitor of PDE4.

26. (Canceled) The method of claim 25, wherein the PDE4 is selected from the group consisting of PDE4D, PDE4D5 and PDE4D7.

27. (Withdrawn) A process for identifying and obtaining a compound for therapy of atherosclerosis, or restenosis, said process comprising administering a compound suspected to be an activator or inhibitor of PDE4 to a non-human animal in which atherosclerosis or restenosis is induced, and measuring the extent of atherosclerosis or restenosis as compared to control-treated animals.

28. (Withdrawn) The process of claim 27, wherein said PDE4 is PDE4D.

29. (Withdrawn) The process of claim 28 wherein the PDE4D is selected from the group consisting of PDE4D5 or PDE4D7.

30. (Withdrawn) The process of claim 28 wherein the PDE4D is PDE4D7.

31. (Withdrawn) The compound of claim 21.

32. (Withdrawn) The compound of claim 25.

33. (Withdrawn) The compound of claim 27.

34. (Withdrawn) A pharmaceutical composition comprising the compound of claim 32 and a pharmaceutically acceptable isomer.

35. (Withdrawn) A method for the treatment of PAOD comprising administering the pharmaceutical composition of claim 34 to a subject having PAOD.

36.(Withdrawn) A pharmaceutical composition comprising the compound of claim 27 and a pharmaceutically acceptable isomer.

37. (Withdrawn) A method for the treatment of PAOD comprising administering the pharmaceutical composition of claim 36 to a subject suffering form atherosclerosis or restenosis.